• Explore /
  • Poster
  • / Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

Abstract Video & Slides Poster

Authors

Karim Fizazi

Karim Fizazi

Institut Gustave Roussy and University of Paris Saclay, Villejuif, France

Karim Fizazi , Aránzazu González del Alba , Özgüroğlu Mustafa , Iwona Anna Skoneczna , Heiko Krissel , Deise Uema , Huanyu Chen , Volker Jean Wagner , Martin Boegemann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

2019-000476-42

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5093)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5093

Abstract #

TPS5093

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Neeraj Agarwal

First Author: Arun Azad

First Author: Julie Nicole Graff

First Author: Evan Y. Yu